PropThink: FDA Confirms Necessity of Ventrus’ Second Phase III

[ACN Newswire] – By Jake KingAs expected, the FDA will require Ventrus Biosciences (NASDAQ:VTUS) to complete a second Phase III study of diltiazem hydrochloride cream (VEN-307) before submitting a New Drug Application … more

View todays social media effects on VTUS

View the latest stocks trending across Twitter. Click to view dashboard